Home › Drug Use and Addiction › NCT07199335
Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
RecruitingPhase 4
A Multi-Center Assessment of an Intervention to Provide Long-Acting Cabotegravir Injectable Pre-Exposure Prophylaxis to People Who Inject Drugs
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * HIV Ab/Ag test (lab-based or rapid) negative at time of enrollment * ≥18 years old * Able to provide informed consent * Have injected non-prescribed drugs within the past 6 months * No prior history of receiving cabotegravir (Note: prior or active use of non-CAB PrEP (\[FTC/TDF or FTC/TAF\]) at screening is allowed, but participant will need to indicate that they prefer to switch to injectable PrEP). * PrEP provider deems cabotegravir use to be appropriate per the applicable prescribing information prior to enrollment in the study. Exclusion Criteria: * Pregnant or breastfeeding people. Should a participant become pregnant, the treating physician will discuss with the participant whether to continue study medication, taking into consideration the risks and benefits of continuing cabotegravir compared with the risk of switching to an alternative recommended PrEP regimen. * Has not had vaginal or anal sex in the past 6 months * HIV indeterminate or positive test result during screening and prior to initiation of CAB PrEP * Already diagnosed with HIV * Taking any of the following medications: Carbamazepine, Rifampin, Oxcarbazepine, Rifapentine, Phenobarbital, Phenytoin
About the study
The goal of this study is to determine the feasibility and impact of delivering long-acting injectable cabotegravir HIV pre-exposure prophylaxis and suite of support services to adults who inject non-prescription drugs who are risk for HIV through known sexual risk.
What is being tested
- APRETUDE (cabotegravir) (drug)
Sponsor: Massachusetts General Hospital · Participants: 100 · Started: Feb 24, 2026
Contact the study team
- Suzanne McCluskey, MD, MSc · Phone: 617-726-9488
Official record on ClinicalTrials.gov — NCT07199335
Locations in the U.S.
| Massachusetts | Fenway Health, Boston Massachusetts General Hospital, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.